March 2023 - Page 12 of 21

TuesdayMar 14, 2023 11:15 am

DGE’s 3rd Risk Based Quality Management Summit to Integrate Quality into Clinical Trials and Ensure Effective Monitoring

Clinical research executives, data management specialists, and industry experts, are all invited to attend the 3rd Risk Based Quality Management Summit that will be held from April 25-26, 2023 at the Le Méridien, in Philadelphia. The summit will be focused on conferring the details of executing data flow process maps, data monitoring tools, audit trails, and quality tolerance limits. RBQM is now being embraced to address the significant increase in research duration, cost, and complexity of clinical research. The newest version of the Good Clinical Practice (“GCP”) quality standard extends the RBM approach to every facet of study execution, implementing…

TuesdayMar 14, 2023 9:45 am

SideChannel Inc. (SDCH), Virgin Voyages Extend Engagement, Adding Virtual Chief Privacy Officer Services to Help Safeguard Data and Information

SideChannel is committed to creating robust and top-tier cybersecurity programs for small and mid-market businesses (“SMBs”), thus helping them protect vital information and customers One of the companies SideChannel has helped achieve this goal is Virgin Voyages, which has expanded its engagement with SideChannel to improve its data privacy efforts with the addition of a virtual chief privacy officer (“vCPO”) from SideChannel The move builds on an earlier engagement, bolstering Virgin Voyages’ goal to protect the important information relating to its crew, sailors, and partners A recent study by IBM Corp. (NYSE: IBM) revealed that the average cost of a…

TuesdayMar 14, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more With its unique product offering, a growing list of patents, and…

MondayMar 13, 2023 2:46 pm

QualityStocksNewsBreaks – Prime Harvest Inc. Secures Reg A+ Qualification, Eyes New Heights of Opportunity

Prime Harvest, a technology focused, full-service cannabis company, recently announced that its Regulation A+ offering, which seeks to raise up to $42 million, had been qualified by the U.S. Securities and Exchange Commission (“SEC”). “The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s state-wide delivery capabilities, as well as general corporate purposes,” a recent article reads. “Dating back to the company’s change in corporate strategy in 2019, a move which saw Prime Harvest transition from its origins as…

MondayMar 13, 2023 2:30 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products

HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection,” a recent article reads. “Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S.…

MondayMar 13, 2023 12:21 pm

QualityStocksNewsBreaks – Iconic Brands Inc. (ICNB) Announces Listing on OTCQB Market

Iconic Brands (OTCQB: ICNB), a leader in the development, design and delivery of alcohol and non-alcohol beverages, today announced that it regained compliance with OTC Markets and is listed on the OTCQB under the ticker symbol ICNB. “We are happy to announce that we have regained compliance with OTCQB Markets,” said Richard DeCicco, chairman of the board and president of Iconic. “The complete integration of our sustainable packaging business is a significant achievement for our company, and we are proud to demonstrate our commitment to our stockholders and investors in regaining our listing status with the OTC Markets. 2023 should…

MondayMar 13, 2023 11:51 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed to evaluate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions, including atopic dermatitis, psoriasis, pruritus and acne. The study is titled “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signalling Pathway.” According to the announcement, study results demonstrate the therapeutic potential of rare cannabinoids in the…

MondayMar 13, 2023 11:34 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals does not hold any deposits or investments at SVB. To view the full press release, visit https://ibn.fm/1EM7p About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

MondayMar 13, 2023 11:05 am

QualityStocksNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Announces Participation in Upcoming Roth Conference

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, will be participating in the 35th annual Roth Conference. The conference, which is slated for March 12–14, 2023, will be held in Dana Point, California, and will feature numerous one-on-one and small-group meetings, as well as analyst-selected fireside chats and thematic industry panels. In addition, leaders from an estimated 400 private and public companies will give presentations. Those companies will come from an array of different industries, including business services, health and wellness, oil and gas, metals and mining, technology, media and agtech, and sustainability.…

MondayMar 13, 2023 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety of mental health related conditions Silo Pharma, a developmental stage biopharmaceutical company has long focused around merging traditional therapeutics with psychedelic research In a study carried out between 2013 to 2016, researchers found that 8.1%…

Site Search

Company Search

Month: March 2023